go-v.orgdoi

Qualification of the Disinfection Efficacy of an Ultraviolet Autonomous Robot for Use in Pharmaceutical Clean Rooms.

Karen Capper, Sean Capper, C Cooke, V Hamers, A Gravett, J Bright · European journal of parenteral & pharmaceutical sciences · 2025

  • DOI 10.37521/ejpps30307
  • Publisher OpenAlex
  • Type article
  • Issued 2025

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

European journal of parenteral & pharmaceutical sciences · OpenAlex · article · 2025

Abstract

The aim of this study was to evaluate the efficacy of a UV-C disinfection robot intended for use on various cleanroom surfaces in the manufacturing facilities at AstraZeneca against a panel of different microorganisms. The studies performed used a method based on the Surface Challenge Test Method EN 13697² to evaluate the reduction in microbial viability after an inoculated surface was exposed to a with a light source emitting 254nm UV-C energy. In this surface challenge test, representative microorganisms were seeded onto coupons representing typical surfaces found in the cleanroom manufacturing areas.

The inoculated coupons were treated with the UV-C light source at multiple dose-levels (mJ/cm²) to generate a death curve per organism, representing the required dose to achieve the desired log reduction as per USP<1072>¹¹ for disinfectant efficacy.

The UV-C light source was tested against a panel of five American Type Culture Collection (ATCC) organisms (Pseudomonas paraeruginosa, Staphylococcus aureus, Bacillus spizizenii, Candida albicans and Aspergillus brasiliensis) and environmental isolates (Micrococcus luteus, Moraxella osloensis, Bacillus Cereus & Penicillium chrysogenum) selected from major AstraZeneca sites, which included those likely to present the greatest challenge to the effectiveness of the UV-C. The robot was qualified and shown to be suitable for use and can achieve a 3-log reduction for bacteria and 2-log reduction for spores depending on the dose applied.

The dose selected by AstraZeneca was 100 mJ/cm² which represented the most practicable dose for the majority of clean room isolates with a higher dose reserved for use if adverse events for moulds or bacterial spores were recovered.

Open the resolved locator · 10.37521/ejpps30307

Metadata licence: OpenAlex metadata (CC0)